Palbociclib and Pembrolizumab in Sarcoma

This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, or alveolar soft part sarcoma).

Trial Details

NCT ID
NCT06113809
Phase
PHASE1
Sponsor
John Rieth
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • Palbociclib
  • Pembrolizumab
Locations (sample)
  • Iowa City, Iowa, United States|41.66113,-91.53017

Key Eligibility Criteria

  • A potential subject must meet all the following inclusion criteria to be eligible to participate in the study:
  • Male or female patients aged \> or = 12 years old
  • ECOG Performance Status of \< or = 2
  • Any patient with the diagnosis of locally advanced, unresectable or metastatic sarcoma for which PD-1 inhibitors are approved (undifferentiated ple…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →